Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017

2023

Article référencé dans le Web of Science WOS:000995480600002

Yade M. S., Dieye B., Coppee R., Mbaye A., Diallo M. A., Diongue K., Bailly Justine, Mama A., Fall A., Thiaw A. B., Ndiaye I. M., Ndiaye T., Gaye A., Tine A., Diedhiou Y., Mbaye A. M., Doderer-Lang C., Garba M. N., Bei A. K., Menard D., Ndiaye D.

Malaria Journal, 2023, 22 (1), p. 167 [7 p.]

Background Malaria control is highly dependent on the effectiveness of artemisinin-based combination therapy (ACT), the current frontline malaria curative treatment. Unfortunately, the emergence and spread of parasites resistant to artemisinin (ART) derivatives in Southeast Asia and South America, and more recently in Rwanda and Uganda (East Africa), compromise their long-term use in sub-Saharan Africa, where most malaria deaths occur.Methods Here, ex vivo susceptibility to dihydroartemisinin (DHA) was evaluated from 38 Plasmodium falciparum isolates collected in 2017 in Thies (Senegal) expressed in the Ring-stage Survival Assay (RSA). Both major and minor variants were explored in the three conserved-encoding domains of the pfkelch13 gene, the main determinant of ART resistance using a targeted-amplicon deep sequencing (TADS) approach. Results All samples tested in the ex vivo RSA were found to be susceptible to DHA (parasite survival rate < 1%). The non-synonymous mutations K189T and K248R in pfkelch13 were observed each in one isolate, as major (99%) or minor (5%) variants, respectively .Conclusion The results suggest that ART is still fully effective in the Thies region of Senegal in 2017. Investigations combining ex vivo RSA and TADS are a useful approach for monitoring ART resistance in Africa.

Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052]

SENEGAL

Fonds IRD [F B010088104]

fdi:010088104